Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Calgary
$27,000.00
Evaluating the Diagnostic Accuracy of the First Canadian Primary Care Clinical Pathway for Alcohol-Related Liver Disease
FY 2025-26
Summary
Alcohol-related liver disease is a growing health issue in Canada. Many adults drink at levels that put them at risk for liver damage, yet early disease often goes unnoticed as symptoms usually appear only after significant scarring has developed. This scarring, known as fibrosis, occurs when the liver is repeatedly damaged and builds up stiff, non-functioning tissue that prevents it from working properly. As a result, many people are diagnosed late, when treatment options are more limited. Although non-invasive fibrosis tests, such as serum biomarkers and ultrasound-based measures, are widely used, their accuracy in detecting serious fibrosis among high-risk drinkers is still under-studied.
To address this gap, my project will evaluate the first Canadian primary-care pathway for alcohol-related liver disease, designed to help primary care providers detect early liver damage in high-risk drinkers. The pathway uses an alcohol-use questionnaire and a blood test called FIB-4, which estimates liver scarring. People with higher FIB-4 scores may then be sent for specialized imaging or referred to a liver specialist. The first part of the project will test how accurate the FIB-4 score is by comparing it to advanced imaging tools that measure liver stiffness to identify optimal cut-offs and reduce unnecessary referrals. The second part looks at how the pathway is being used in real clinics, how many providers use it, how many patients are screened, and whether referrals to liver specialists are timely and appropriate. By improving early detection and giving primary care physicians an easy-to-use tool, this work has the potential to prevent severe liver disease, support better patient care, and reduce strain on specialist services across the Calgary Health Zone.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572817
Name
Lambert Taryn E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the Diagnostic Accuracy of the First Canadian Primary Care Clinical Pathway for Alcohol-Related Liver Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Alcohol-Related Liver Disease; Audit-C; Clinical Pathway; Diagnostic Accuracy; Early Detection; Fibrosis-4; Non-Invasive Testing; Primary Care; Referral Pathways; Risk Stratification
Abstract
Alcohol-related liver disease is a growing health issue in Canada. Many adults drink at levels that put them at risk for liver damage, yet early disease often goes unnoticed as symptoms usually appear only after significant scarring has developed. This scarring, known as fibrosis, occurs when the liver is repeatedly damaged and builds up stiff, non-functioning tissue that prevents it from working properly. As a result, many people are diagnosed late, when treatment options are more limited. Although non-invasive fibrosis tests, such as serum biomarkers and ultrasound-based measures, are widely used, their accuracy in detecting serious fibrosis among high-risk drinkers is still under-studied.
To address this gap, my project will evaluate the first Canadian primary-care pathway for alcohol-related liver disease, designed to help primary care providers detect early liver damage in high-risk drinkers. The pathway uses an alcohol-use questionnaire and a blood test called FIB-4, which estimates liver scarring. People with higher FIB-4 scores may then be sent for specialized imaging or referred to a liver specialist. The first part of the project will test how accurate the FIB-4 score is by comparing it to advanced imaging tools that measure liver stiffness to identify optimal cut-offs and reduce unnecessary referrals. The second part looks at how the pathway is being used in real clinics, how many providers use it, how many patients are screened, and whether referrals to liver specialists are timely and appropriate. By improving early detection and giving primary care physicians an easy-to-use tool, this work has the potential to prevent severe liver disease, support better patient care, and reduce strain on specialist services across the Calgary Health Zone.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lambert, Taryn E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~